

REVIEW

UDC 577.1/546

doi: <https://doi.org/10.15407/ubj89.02.005>

RHENIUM-PLATINUM ANTITUMOR SYSTEMS

A. V. SHTEMENKO¹, N. I. SHTEMENKO²¹Ukrainian State University of Chemical Technology, Dnipro, Ukraine;²Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;e-mail: n.shtemenko@i.ua

This review provides an overlook of design (in short), antitumor and other biological activity of quadruple-bonded cluster dirhenium(III) compounds and their synergism with cisplatin. In particular, we describe the work of the rhenium-platinum antitumor system (introduction of rhenium and platinum compounds). Among known metal-based anticancer drugs and drug candidates dirhenium(III) compounds differ profoundly due to their strong antiradical and antioxidant properties determined by quadruple bond unsaturation. Such advantages of metal complexes as more expressed redox chemical properties should be exploited for creating more efficient anticancer drugs. Combination of drugs leads to synergistic effects and/or to lowering toxicity of platinum compounds and is very promising in cancer chemotherapy. The review covers the following items: design of quadruple bonded dirhenium(III) clusters, their spectral and antiradical properties (in short); interaction of the dirhenium(III) compounds with lipids and formation of liposomes; interaction of the dirhenium(III) compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia; anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system; anti-anemic and antioxidant properties of the dirhenium(III) compounds in the model of tumor growth; interaction of the dirhenium(III) compounds with nucleobases and DNA. Some modern trends in the field of bioinorganic and medicinal chemistry are also considered regarding their connection to the rhenium-platinum system efficiency: use of combinational therapy and nanomaterials; involvement of some biologically active ligands and redox-activation strategy, etc.

Key words: rhenium, platinum, antitumor activity, antioxidant, antihemolytic, hepato-, nephrostabilizing activity.

After discovery and wide use of cisplatin there is a growing interest in transition-metal-containing drugs. Various strategies have been applied for the design of novel drugs with an improved toxicological profile that have been reviewed in detail in [1-7]. It is commonly accepted that many advantages that metal complexes have in the comparison with organic molecules, especially their versatile redox chemistry, should be used for creating more efficient anticancer drugs. An important paradigm for the development of new antitumor pharmaceuticals is represented by dinuclear carboxylate complexes of rhodium, ruthenium and rhenium

with so-called 'chinese lantern' structure [8-10]. It was postulated that such species could bind to DNA, inhibit DNA replication and protein synthesis [11, 12] in a manner similar to cisplatin [4, 13, 14]. Among this group, the dirhenium(III) compounds may be recognized as especially promising candidates for clinical development due to their very low toxicity [15]. This issue is especially important considering severe limitations for clinical use of some cytostatics as cisplatin originating in its neuro-, hemato-, hepato- and nephrotoxicity [16-18]. Cisplatin, as a systemic anti-proliferative agent, preferentially kills dividing cells, primarily by attacking their DNA at

some level (synthesis, replication or processing) and binds to non-DNA targets. It is not truly selective for cancer cells and damages also proliferating normal cells such as those in the bone marrow and gut epithelium.

A lot of studies have explored the potential of platinum-based combination therapy [19] that means to combine one, two or more known non-platinum anticancer drugs with a platinum compound, for example [20-25]. Such a combination leads to synergistic effects and/or to lowering toxicity of platinum-based drugs and is very promising in cancer chemotherapy. Our work is an example of successful use of two anticancer agents with different mechanism of action in tumor suppression.

We summarize here recent activity and our modest experience in the field of chemistry and biochemistry of rhenium clusters. Herein, we highlight anticancer and modulation properties of these compounds and try to present future trends in their application.

Design of quadruple bonded dirhenium(III) complexes, their spectral, antiradical properties and formation of liposomes (in short)

Till the second half of the 20th century a possibility to realize δ -bonding between two metal atoms was only a prognosis of chemists-theoreticians. Quadruple bond ($\sigma^2\pi^4\delta^2$) may be formed only between two atoms of transition elements, i.e. valence level of which contain d-electrons. Existing of such a bond was suggested first by Kotelnikova and Koz'min [26] and confirmed by Cotton [27] half a century ago in the $[\text{Re}_2\text{Cl}_8]^{2-}$ anion. Structure of this ion in the complexes with amino acids was later confirmed by us.

Cluster formation stabilized unusual for rhenium state of oxidation +3. Dinuclear fragment Re_2^{6+} with the quadruple metal-metal bond plays role of a single central atom of complex formation with an overall coordination number 10. This makes it possible to choose ligands environment increasing the stock of new compounds with certain properties.

The history of this discovery includes scientific competition between two research groups headed by Drs. Kotelnikova and Koz'min (Institute of General and Inorganic Chemistry, Academy of Science of the USSR, Moscow) and by Prof. Cotton (Massachusetts Institute of Technology, Cambridge, USA). Each side describes this discovery in a different way

[28, 29], paying the most attention to the structural aspect, but the main important result of mutual work was the creation of a new branch of chemical knowledge – chemistry of multiple bonded cluster compounds of transition metals.

In spite of a significant progress in theoretical investigations of quadruple metal-metal bond [30] the stock of the quadruple bonded compounds was limited by imperfection of synthetic methods and approaches during following 10 years. This problem was unzipped in the beginning of 80th by elaboration by us of new and universal synthetic methods of dinuclear cluster compounds of rhenium(III). Depending on some conditions of the synthetic procedure it was possible to obtain dirhenium(III) derivatives: octahalogenides; dihalogenotetra- μ -carboxylates; trihalohenotri- μ -carboxylates; *cis*-tetrahalogenodi- μ -carboxylates; *trans*-tetrahalogenodi- μ -carboxylates [31-34]. Some structural types of the dirhenium(III) compounds are presented in Fig. 1.

The main structural unit – dinuclear fragment Re_2^{6+} in this family is a center of complex formation. This review focuses on halogeno- μ -carboxylates of dirhenium(III) as they have been shown to be interesting for biochemical trials.

Dinuclear rhenium(III) compounds with metal-metal bond belong to the class of d^4 - d^4 dimers that have electronic configuration of $\sigma^2\pi^4\delta^2$ in the ground state according to quantum chemical calculations, the order of the metal-metal bond is 4 and in the case of an electron capture it is 3.5.

Quadruple bond (delta-, δ -bond) is unique, absent in biologically occurring molecules and may be formed only by atoms of transition metals that contain d-electrons. The fourth component of the Re-Re quadruple bond has much less energy of $\delta \rightarrow \delta^*$ electron transition than $\pi \rightarrow \pi^*$ electron transition, that is a reason of absorption in the long-waved visible area in electronic absorption spectra (EAS) and of antiradical, antioxidant properties of the quadruple-bonded dirhenium(III) compounds. These compounds have more unsaturation than double-bonded known antioxidants, containing π -bonds, thus *a priori* may compete in being the mightiest antioxidants.

EAS of dinuclear Re_2^{6+} carboxylates were described in [34, 35]. The analysis of energy position and intensity of the most long-waved band in EAS solutions of rhenium compounds let to assign it to $\delta \rightarrow \delta^*$ electron transition. Gradual substitution of Cl ligands around Re_2^{6+} center by carboxylic ligands




Fig. 1. Some structural types of cluster dirhenium(III) compounds

was accompanied by hypsochromic shift of this band and expected decreasing of its intensity:

$\text{Re}_2\text{Cl}_8^{2-}$ – 14 700 cm^{-1} ($\epsilon \sim 1200$), *cis*- $\text{Re}_2\text{Cl}_4(\text{RCOO})_4\text{L}_2$ – 15 625 cm^{-1} ($\epsilon \sim 500$), *trans*- $\text{Re}_2\text{Cl}_4(\text{RCOO})_4$ – 16130 cm^{-1} ($\epsilon \sim 700$), $\text{Re}_2\text{Cl}_3(\text{RCOO})_3$ – 18 000 cm^{-1} ($\epsilon \sim 300$) and $\text{Re}_2(\text{RCOO})_4\text{Cl}_2$ – 20 000 cm^{-1} ($\epsilon \sim 200$). These data let us use EAS as a reliable method of identification of dinuclear cluster rhenium(III) compounds and made it possible to investigate some mechanisms of their interactions with biological molecules.

Antiradical properties of dirhenium(III) cluster compounds were shown first in the model of chain radical reaction – oxidation of benzyl alcohol by oxygen [36], then by studying reactions of dirhenium(III) compounds with some stable radicals [37, 38]. It was shown that the radical chain was interrupted by two reactions of quadruple bond and the oxidation process was stopped. The reaction of dirhenium(III) carboxylates with stable radicals was more effective than that of some known antioxidants and showed the dependence of the kinetics on the structure of the rhenium complex: interaction of a

radical with tetracarboxylates took 30-35 days; with tricarboxylates – several days; *cis*-tetrahalogenodi- μ -carboxylates – a day and *trans*-dicarboxylates – several seconds. Thus, in our hands we keep the traps for radicals with different abilities to react. As the peroxide oxidation of lipids (POL) in cells is a radical chain reaction, the idea emerged about possibility for dirhenium compounds to break POL *in vivo*.

Due to their reactive nature, most of the drugs are rapidly inactivated by binding to proteins or other molecules upon entering the organism and never reaching the tumor in an active form that is considered a major cause of much dose-limiting toxicity [39]. One approach to try and to circumvent these drawbacks is to encapsulate the drug in liposomes. An advantage of liposomes also is that the encapsulated drug is protected from (rapid) degradation and excretion, and it eliminates the binding to neutralizing targets (for example, glutathione in the case of cisplatin). Liposomes of cisplatin can be cross-linked in a way to exhibit favorable pharmacokinetics, i.e., increased serum half-life and improved targeting

tissues or cells of interest [39]. Liposomal cisplatin was shown to be more effective and less toxic to non-cancer cells in liposomal forms in comparison with solutions. Also, long-circulating liposomes are considered to overcome drug resistance [40-43] and in general present a promising delivery system for cisplatin-based cancer treatment.

Most of dirhenium(III) compounds are low-soluble and not stable in water solutions and just liposomal forms of cluster rhenium compounds allow introducing them successfully to biological experiments. Further investigations of the structure and properties of cluster rhenium compounds with different organic ligands including phosphate groups made it possible to discuss the mechanism of interaction of the compounds with membrane lipids (phospholipids) inside liposomes.

In the spectra of $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ in chloroform solution there is a band in the area of $20\,000\text{ cm}^{-1}$ that is relevant to $\delta \rightarrow \delta^*$ electron transition of dirhenium tetracarboxylates as it was previously described.

In the phosphatidyl choline mixture a new absorption band in the area of $15\,600\text{--}14\,000\text{ cm}^{-1}$ appeared that increased and shifted with time closer to $14\,000\text{ cm}^{-1}$. At the same time the absorption in the area of $20\,000\text{ cm}^{-1}$ (characteristic of dirhenium(III) tetra- μ -carboxylates) decreased. Similar shifts were found in the spectra of other representatives of this structural type – $\text{Re}_2(\text{C}_3\text{H}_7\text{COO})_4\text{Cl}_2$, $\text{Re}_2(\text{PhCOO})_4\text{Cl}_2$, $\text{Re}_2(\text{AdCOO})_4\text{Cl}_2$ in their chloroform solution with phosphatidyl choline [35, 44, 45]. This fact reflected the process of gradual substitution of carboxylic ligands on phosphate groups of phosphatidyl choline around Re_2^{6+} -centre. The coordination is formed as a monodentate coordination of phosphatidyl choline to equatorial positions of the Re_2^{6+} -centre with destruction of the conjugated Re-carboxylic cycles. Hence, the energy of δ -bond splitting is decreased during interactions of dirhenium carboxylates with phosphatidyl choline.

Liposomes from phosphatidylcholine and other lipids loaded with dirhenium(III) compounds are easily prepared by thin-film method [44, 45], have average size 100-150 nm. They are stable during 8-10 days demonstrating the protective functions of the lipid coating against hydrolysis.

The quadruple bond in liposomes was stored during this period, that was confirmed by EAS.

Recently we have developed an efficient strategy for co-encapsulation of both dirhenium and plati-

num based drugs into 100–105 nm scale liposomes [44]. The obtained liposomes with two drugs exhibit different shape and spectral characteristics from those incorporating only one drug. Such “nanobins” can be used in anticancer trials, that allows changing surface lipid component in order to obtain more stable vesicles loaded with targeted components with different ratio.

To sum it up, liposomes loaded with rhenium compounds cluster center Re_2^{6+} were not destructed during long period, but there were some changes in ligand environment. These changes took place due to the above described substitution of carboxylate or chlorido ligands by phosphate ones of phosphatidyl choline, which the coating is built of. In the case of dirhenium(III) compounds which contain quadruple bond, encapsulation to lipids led not only to the known advantages such as protection from hydrolysis, long-living, etc., but also to additional activating of the main biologically active unit – the quadruple bond. Elaboration of combined liposomal nanotechnology led to encapsulation of the rhenium-platinum system with definite ratio in one liposome.

Interaction of dirhenium(III) cluster compounds with erythrocytes and their antihemolytic activity in the models of hemolytic anemia

As hemolysis and senescence of human red blood cells (RBC) is an intensive radical process [46] we checked if antiradical properties of binuclear cluster rhenium(III) compounds would be executed in this model. Hemolytic erythrogramm (dependence of kinetics of Hb outcome on cells with time under influence of hemolytics – NaCl, HCl, etc.) of normal human RBC consists of groups of cells with different resistance to hemolysis (Fig. 2, A).

Incubation of erythrocytes *in vitro* with cluster rhenium compound $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ led to formation of a group of cells with higher resistance to acidic hemolysis (Fig. 2, B). Maximum of hemolysis time shifted to 6 minutes. It was shown that $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$, was a unique stabilizer of RBC against acidic hemolysis in the wide range of tested concentrations [47].

Some dirhenium(III) compounds, containing adamantanecarboxylic ligands, were not active in that model at all, i.e., did not influence the stability of normal RBC against acidic hemolysis. But they had a stabilizing effect only in old RBC with lower initial resistance to hemolysis (Fig. 2, C). Unloaded




Fig. 2. Hemolytic erythrograms. **A** – Human normal RBC: **a** – sector of erythrogramm (24%) that corresponds to old RBC with low stability; **b** – sector of erythrogramm (50%) that corresponds to adult RBC with average stability; **c** – sector of erythrogramm (26%) that corresponds to young RBC with strong stability. **B** – Human normal RBC (solid line) and after incubation with $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ (line with cubes). **C** – Old rats RBC incubated with: **1** – unloaded liposomes, **2** – liposomes loaded $\text{cis-Re}_2(\text{AdCOO})_2\text{Cl}_4(\text{CH}_3\text{CN})_2$, **3** – liposomes loaded $\text{cis-Re}_2(\text{AdCOO})_2\text{Br}_4(\text{CH}_3\text{CN})_2$

liposomes had some tiny stabilizing effect, shifting the maximum of hemolysis from 1.0 to 1.9 min with no visible changes for the whole time of hemolysis. It is known that empty liposomes had therapeutic effect [48] due to binding to the cell surface and endocytotic uptake of phosphatidyl choline by cell membranes that have protective properties. Interaction of RBC with liposomes loaded with rhenium cluster compounds led to the shift of the erythrograms to right side and increased significantly the parameters of the hemolytic process that showed the stabilizing properties of the rhenium compounds. This RBC model with the senescing RBC appeared to be very sensitive to the structures of the compounds, where

the only difference was in halogens Cl and Br located in axial positions of the quadruple bond. Thus, the stabilizing effect depended on both the structure of the rhenium substance and properties of the RBC membranes.

Binuclear cluster fragment Re_2^{6+} actively reacted with artificial radicals *in vitro*, however the rate of such interaction strongly depended on the ligand environment of the cluster Re_2^{6+} . Besides, the reaction rate decreased with an increase of induction effects of alkyl groups in the ligands. This dependence did not coincide with that obtained by the investigations of artificial radicals shown herein and is more complicated, as the latter includes wider and more

multifunctional interactions in living cells. Presented data showed positive future prospects for Re_2^{6+} -substances applications as therapeutic agents due to their low toxicity and antiradical properties that are put into effect by δ -component of quadruple Re–Re bond and revealed in living RBC.

Chemically induced anemia (caused by introduction of lead acetate or phenylhydrazine, etc.) led to formation of non-stable population of erythrocytes in comparison with control on the first stage of anemia development.

Introduction of the rhenium compound to experimental rabbits led to a decrease of the non-stable population and increase of stable population of RBC [35]. In the second phase of anemia the formation of very stable population of RBC was noticed. High fragility of RBC and low hematocrit are the signs of hemolytic anemia [46,49]. The ability of RBC to deform is a very important requirement for these cells to navigate narrow capillaries *in vivo*. They reversibly transform from discocytes echinocytes and then irreversible destructions start – the process of hemolysis or haemoglobin outcome. The decrease in deformability or membrane defects may play a significant role in hemolysis, caused by different factors. In our experiments quantity of discocytes sharply decreased under introduction of phenylhydrazine while quantity of destructed RBC increased. Introductions of tocopherol and a rhenium compound shifted the picture of red blood to the normal state. Introductions of the rhenium compounds in liposomal forms were especially effective. In these experiments we demonstrated the antihemolytic activity of dirhenium(III) cluster compounds *in vivo*, that were not only the result of RBC membrane-stabilizing properties of the compounds, but involved more complex influence on the system of red blood of experimental animals.

Anticancer activity of dirhenium clusters and work of the rhenium-platinum antitumor system

In 1983 the dirhenium cluster compound – $\text{Re}_2(\text{EtCOO})_2\text{Br}_4(\text{H}_2\text{O})_2$ – was proved to have varying degrees of effectiveness against sarcoma S-180, leukemia P-388, and melanoma B-16, with particularly good results against B-16 by Eastland and co-workers [50]. This compound was found to be quite susceptible to decomposition in aqueous solutions. In addition, the complex required very high doses to achieve maximum efficiency also being the

result of the compound instability. It is readily decomposed into insoluble rhenium oxide requiring therefore its considerable amount to be injected in order to have a significant quantity to reach tumor sites. Since the discovery of antitumor activity of $\text{Re}_2(\text{EtCOO})_2\text{Br}_4(\text{H}_2\text{O})_2$ this field remained actually unexplored.

Our investigations of anticancer activity of dirhenium cluster compounds started in 2000 with experiments on Guerin's carcinoma (T8). T8 is a rat's specific solid tumor that is widely used in the trials of different chemotherapeutic agents and is sensitive to cisplatin [51, 52]. Growth of transplanted cells in control groups of xenografts during 21 days was very rapid, tumors occupied approximately 1/3 of the animal weight on the last day of the experiment.

The period of 21 days after T8 cells transplantation is considered crucial for survival, the massive deaths of the control animals are usually started, that is in line with previously described aggressive characteristic of this type of tumor. The description of our experiments is also presented, details you may find in [44, 49, 53-56].

We started from the first types of experiments (I) – introductions of rhenium clusters in solutions in large doses. High-dose rhenium therapy caused 20-30% inhibition of tumor growth that was independent of the quantity of introduced substances. No deaths were observed in groups, where rhenium compounds were introduced and no visible changes in the liver, spleen, kidneys, skin, lung or brain were defined. But brown precipitate – products of the cluster rhenium compounds decomposition – was found in the peritoneal cavity, being more intensive in animals of the group, where the quantity of introduced compounds was especially large. That coincided with the results obtained by Eastland's group. The procedure used in experiments of type I cannot be considered as reasonable, since the most of the preparation decomposed and turned into insoluble rhenium dioxide. This fact can also explain the absence of a dose effect. Rhenium cluster compounds clearly demonstrated impossibility to be introduced in solutions and in high acute dose.

As far as liposome forms of dirhenium compounds were elaborated, we used the procedure II – introduction of only rhenium compound at a dosage according to the scheme of antioxidant therapy. The inhibition of tumor growth during the first two periods of the observation was reached, but it was not so effective at the last stage (Fig. 3, Table).




Fig. 3. Volumes of tumors in experiments with Re1 – $Re_2(i-C_3H_7COO)_4Cl_2$, dynamics of tumor growth in a control group and in a group with Re2 – $cis-Re_2(AdCOO)_2Cl_4(CH_3CN)_2$ in liposomes treatment

Volumes of tumors in vivo on three stages of development

Group of animals	Stage of tumor development		
	I (10-13 days)	II (13-17 days)	III (17-21 days)
Control	10–50	30–70	60–100
Cisplatin	4–5	15–30	5–35
[Re1]lip	5–10	15–25	60–82
Cisplatin + [Re1]lip	4–5	3–5	0–2

The dynamics of tumor growth, shown on Fig. 3, is typical of the most of tested rhenium compounds, introduced according to procedure II. Inhibition of the tumor growth under introduction of rhenium compounds according to method of introduction II reached usually 30-45%.

Cluster rhenium compounds, solely introduced in liposome form did not have so strong inhibitive mechanism of interaction with cancer cells as cisplatin, thus this mechanism differs from that of cisplatin. It was shown [57] that different categories of chemically induced and consecutively developing tumors – hyperplasia, adenoma and carcinoma – featured various sensitivity to different agents on some tumor growth stages. It means that each stage of tumor progression has special signal transduction system and special response to different chemotherapeutic agents.

This consideration may partly explain synergistic effect of the rhenium cluster with cisplatin: introduction of cisplatin solution on the 9th day and ten times introduction of the rhenium compound in liposomes with final ratio of platinum and rhenium ratio 1 : 4 (method of introduction III) – the rhenium–platinum antitumor system. A particularly significant decrease in the measured tumor

volumes was found in the groups, where cisplatin and ReI were introduced together (Fig. 3, Table, Group [ReI]lip + cisPt). In these groups deaths were not observed during 21 days of the experiment and reduction of the tumor growth was more effective in comparison with cisplatin alone, even at the last stages of tumor development. Most of the experimental animals had no tumors at all and this kind of chemotherapy can be considered extremely effective.

It suggests that differing mechanisms of tumor inhibition on different stages of progression by rhenium and platinum compounds resulted in the inhibition of the tumor at the last stage of development. A lot of dirhenium(III) compounds were tested in this experiment (Fig. 4) [44, 53-56], that allowed us to present the rhenium-platinum antitumor system.

The efficacy of the rhenium-platinum antitumor system with the use of some representatives of rhenium cluster compounds of such types as tetracarboxylates, *cis*-dicarboxylates, *trans*-dicarboxylates of dirhenium(III) complexes was essential, the tumor inhibition reached 95-100%. Our first conclusion about the antitumor system efficiency independence of the ligands nature in the molecule of dirhenium clusters was changed after investigation of the homologues of alkyldicarboxylates (Fig. 4, B) [56], where we found the correlation between the length of alkyl chain in carboxylic groups and ability to inhibit the growth of tumor. Really, the dependence in antitumor efficiency grew in the range methyl < ethyl < propyl < butyl < pentyl substituent R in the structure of dicarboxylates of dirhenium, i.e. with hydrophobicity of the alkyl chain.

Then a new dirhenium(III) dicarboxylate complex *cis*-[Re₂(GABA)₂Cl₅(H₂O)₂]Cl was shown to possess appreciable antitumor activity being introduced alone, which was higher than those of the previously investigated alkyldicarboxylates (up to 60%) (Fig. 4, C) [54]. This may find further applications for the development of new antitumor dirhenium(III) species with active ligands. Studies for the synthesis of active dirhenium(III) compounds involving zwitterionic aminocarboxylate ligands, curcuminoid, indolylacetic, etc. ligands are in progress. Our new findings show that both the hydrophobicity (and other possible functions) of ligands and the ligand charge play a significant role in DNA-interactions and in the antitumor activity of the dirhenium complexes.

Systematic studies of structure-activity relationships among dirhenium complexes have pro-

vided insight into the molecular characteristics that control their activity [58-63]. In particular, a study performed on a series of dirhenium carboxylate derivatives that exhibit cytostatic activity against the Ehrlich ascites tumor, leukemia L1210, and sarcoma 180 cells, revealed that the activity of this series increases with the lipophilicity of the bridging carboxylate alkyl groups but that further lengthening of the carboxylate group beyond the pentanoate reduces their therapeutic efficacy [60]. Taking this into account as well as the fact that dirhenium isobutyrate analogs were anticancer active ones, we studied in detail properties of the Re-Pt system with rhenium complex with pivalic acid as ligands, namely *cis*-Re₂[(CH₃)₃CCOO]₂Cl₄·2DMSO [55].

The inhibition of the tumor growth after introduction of cisplatin in solution (group T8+cisPt) was rather effective in this model and the inhibition of the tumor growth reached up to 84%. The mortality of the experimental animals was very high in both T8 and T8+cisPt groups (up to 35%), which demonstrates the carcinoma aggressiveness and cisplatin toxicity. The introduction of the dirhenium compound alone led to reduction of the tumor size by 57.45% and no rat deaths were recorded in this group. The antitumor effect of Re₂[(CH₃)₃CCOO]₂Cl₄·2DMSO (57%) is greater than the effect found for other dirhenium compounds, such as Re₂[(CH₃)₂COO]₄Cl₂ with shorter carboxylate chains (by 28–30%) [56] or compared to the effect of [Re₂(GABA)₂Cl₅(H₂O)]Cl·2H₂O (by 60%) [51] with the same model. Previously, we proposed that the cationic complex Re₂(GABA)₂Cl₅(H₂O)]Cl·2H₂O interacts with DNA more effectively than the neutral alkyldicarboxylates [56] by taking into account that the positive charge may facilitate DNA binding due to electrostatic interactions. Our new findings in this report show that both the hydrophobicity of the alkyl ligands and the ligand charge play a significant role in antitumor activity of the dirhenium complexes.

A very significant effect was observed for the group, where cisplatin and Re₂[(CH₃)₃CCOO]₂Cl₄·2DMSO were introduced together. Remarkably, in this case, no deaths were registered for the entire 21-day period of the experiment, while the reduction of the tumor growth was more effective than that of T8+cisPt group and many of the experimental animals had no tumors at all. Therefore, it is obvious that this type of combined chemotherapy with Re₂[(CH₃)₃CCOO]₂Cl₄·2DMSO is very effective and comparable to the cases of previously investi-




Fig. 4. Antitumor properties of the rhenium-platinum system with different cluster rhenium compounds in comparison with cisplatin. **A** – Dynamics of tumor growth under influence of cisplatin (blue), $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ and cisplatin (rose); **B** – Weight of residual tumors in experiments with cisplatin and rhenium(III) dicarboxylates. **C** – X-ray structure of *cis*- $[\text{Re}_2(\text{GABA})_2\text{Cl}_5(\text{H}_2\text{O})_2]\text{Cl}$ and weights of residual tumors

gated compounds. Additionally, no significant structure-efficacy relationship is observed in the case of combined treatments as recorded in treatments with single rhenium compounds. But the best results were obtained, when both compounds were put in one liposome in the ratio 1 : 4 [44]. The tumor was reduced from the first days of the experiment and no harmful effects were noticed for the liver, kidneys and RBC morphology. These results demonstrated efficacy of the encapsulated Re-Pt system into lipid coating and showed the way to enhance the antitumor properties of the system (and other preparations) by this procedure.

In a thorough theoretical discussion of chemoprevention, Lippman and Hong [64] stated that our understanding of neoplastic evolution considerably improved and led to revolution in drug development – a turn from toxic drugs to molecular targeting. Identifying multiple molecular targets for effective combinations of preventive agents is a major focus of chemoprevention or chemotherapeutic study. Many studies were carried out to evaluate the combinations of antitumor drugs, for example interferon resulted in synergistic interactions with antitumor ruthenium complexes [65]. New 5-fluoracil analogues and folate antagonist, the inhibitor of topoisomerase I irinotecan and the third-generation platinum compound oxaliplatin [66-68] developed, based on distinct mechanism of cytotoxicity and resistance, as well as effective combination patterns show themselves to be very promising.

The known affinity of sulfur for platinum complexes has resulted in the investigation of so-called “protecting agents” with a view to correcting side-effects of platinum therapy, without reducing its antitumor activity too much (for example, nucleophilic sulfur compounds, such as sodium thiosulfate (STS), biotin, glutathion, sodium 2-mercaptoethanesulfonate (mesna) and its oxidized S-S-bridged dimer (dimessna, BNP-7787)). The protective effect of these compounds is prevention or reversal of Pt-S adducts in proteins. It has been shown that protein-bound cisplatin cannot be released by STS, although STS is able to break the Pt-thioether bond in methionine model systems. Possible ReI functioning as “protecting agent” has not been studied, but there is a more feasible side of its mechanism of action. Possible mechanisms and numerous examples of cisplatin action modulation are discussed in detail in the review of Fuertes et al [19, 68], where biochemical modulation is formulated as a manipulation of

cellular biochemical pathways by chemical agents to produce selective enhancement of the efficiency of antitumor drug. Biochemical modulation of mechanism of action platinum-based compounds is considered as a rather efficient and promising strategy in cancer treatment, even in comparison with new metal-based drugs. This definition – biochemical modulation – includes possible mechanisms of complex action of several substances mentioned above. Among the most important factors for understanding possible enhancement mechanisms of the rhenium compounds we should underline the following: (i) enhancement of cisplatin accumulation as it was shown for dipyrindamole, amphotericine B and cyclosporine. An increase in cell membrane permeability is one of the known properties of these substances that lead to the enhancement [69]. Our previous works showed the unusual ability of some rhenium substances to increase conductivity of artificial lipid membrane [70, 71] and the formation of membrane pores which provoke K⁺ efflux; ii) platinum detoxification by glutathione. Having strong reducing potential, showed herein, cluster rhenium compounds may interfere with the glutathione system both at the substrate level and at the enzyme level of enzymes as was demonstrated with example of L-SR-buthionine sulfoximine (L-BSO), an inhibitor of γ -glutamyl-cysteine synthetase; iii) intracellular ATP-level regulation, which determines apoptotic death as was shown for a complex of substances (MAP-regime); cluster rhenium substances may change the bioenergetic cellular index as they are active antioxidants; iv) interactions with ceramide-sphingosine-sphingosine-1-phosphate rheostat that determined balance between survival and apoptosis as rhenium compounds were shown to interact with phosphate groups in liposomes.

The occurrence of drug resistance is one of the main challenges for cancer chemotherapy [72-76]. Tumor resistance to anticancer drugs has multiple and complex mechanisms. From the contemporary knowledge a heterogeneous population of tumor cells contains inherently chemoresistant (intrinsic resistant, cancer stem cells or cancer initiating cells) that drive tumorigenesis; and other cells, initially responsive, but acquired mutations and became resistant after drug application (secondary resistant or acquired resistance). Resistant to cisplatin Guerin carcinoma (T8*) – is a very convenient model for investigation of efficacy of new drugs for overcoming cisplatin resistance [76]. In our experiments cisplatin

reduced T8* effectively (only by 30-35%). Application of the Re-Pt system led practically to elimination of the resistant tumor. Resistant cancer cells display a rich repertoire of self-defense biochemical reactions. But among plenty of methods proposed to overcome drug resistance, the following two most promising ones were named: a combination of drugs targeting alternative pathways simultaneously and employment of immunotherapy in the form of monoclonal antibodies and vaccines that can augment immune response against cancer [72]. Also, some metal complexes were proposed for therapy and diagnosis of drug resistance [77]. This allows us to suppose, that combination of two anticancer metal-containing drugs used by us with different mechanism of action may be useful to overcome drug resistance.

Investigations of morphology of residual tumors showed unusually large quantities of gigantic cells in the tumor tissues (Fig. 5, A), isolated from

tumor-bearing animals where rhenium-platinum system was applied, together with usually observed chemically caused pathomorphological changes as fibrosis, necrotic, apoptotic, chimeric mitotic cells, etc.

Gigantic cells are common for chemically induced morphological changes in cancer cells but there is not final recognition about their destiny – are they ‘terminal’ or it is some kind of ‘delay’ in cancer progression [78] that is far beyond our issue matters. But formation of large quantities of giants in the residual tissue of T8 in experiments where rhenium-platinum antitumor system was applied in comparison with experiments, where cisplatin or rhenium substances were solely introduced allowed us to suggest that combination of two metal based compounds switched some additional signal transduction pathways important for cancer cells survival or death.




Fig. 5. A – Gigantic cells in residual T8 tissue. B, C and D – Influence of rhenium–platinum antitumor system, where Re1 – $\text{Re}_2(i\text{-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ and its components on the growth of leukemic cells Jurkat

Results of the experiments with human leukemic cells (Fig. 5, B, C, D) supported this observation as influence of the system was more effective (B) and more pro-apoptotic (C, D) to this kind of cancer cells in comparison with the influence of cisplatin and rhenium compound.

Further our investigations of anticancer properties of the rhenium-platinum antitumor system were aimed to involve new dirhenium compounds with biologically active ligands and to elaborate nanotechnology with the use of combined liposomes [44, 55]. The antitumor effect of some newly synthesized dirhenium compounds with biologically active ligands having been introduced alone, was greater than the effect found for other dirhenium compounds, such as *cis*-[Re₂(GABA)₂Cl₅(H₂O)]Cl·2H₂O in the same model [not published results]. Previously, we supposed that this cationic complex interacted with DNA more effectively than the neutral alkylcarboxylates, owing to the positive charge that may facilitate DNA binding due to electrostatic interactions.

Antianemic and antioxidant properties of the rhenium(III) compounds in the model of tumor growth

Anemia is a common complication of malignancies [79-83]. Cancer can give rise to anemia by various routes, the mechanisms behind cancer-related anemia's are very complicated, remain debatable [62, 63] and only some aspects are discussed herein. A negative impact of anemia on the outcome of cancer patients treated with chemo-, radiotherapy is well-known, with a reduction of treatment efficacy by anemia-induced tumor hypoxia being a popular explanation. Bone marrow is a very active tissue, and cancer treatment can sometimes be very hard on normal bone marrow, causing anemia. Drug treatment is most likely to cause anemia in this way, particularly with drugs such as platinum-based drugs. New lines of evidence suggest that abnormalities in the production of erythropoietin (EPO) in kidney tissue are involved. The hypoproliferative state in anemia of cancer appears to be related to either decreased EPO production by injured kidney or impaired bone marrow response to EPO [84-86]. The use of EPO subsequently expanded to include the correction of drug-induced anemia (such as with chemotherapy drugs) and other types of cancer-related anemia. Under influence of cisplatin deep destructions in the system of RBC of tumor-bearing animals occurred:

resistance of RBC greatly decreased (Fig. 6, A), maximum of hemolysis (1.5 min) shifted to left side in comparison with intact animals (3.5 min).

Under cisplatin introductions quantity of discocytes sharply decreased and quantity of destructed RBC increased (Fig. 6, C), that underlined the harmful influence of the cisplatin therapy on the production of RBC.

Use of rhenium(III) carboxylates of tetracarboxylates and *cis*-dicarboxylates types led to increase in RBC resistance (Fig. 6, B), hematocrit, quantities of discocytes and to decrease in quantities of destructed RBC (Fig. 6, C). Similar RBC-supporting functions of rhenium(III) carboxylates of such types of compounds were shown to manifest in the model of tumor growth without cisplatin [55] and in the models of chemically induced hemolytic anemias [35]. Interestingly, that one of representatives of the type of *trans*-dicarboxylates – *trans*-Re₂(C₃H₇COO)₂Cl₄ did not influence so positively the RBC properties, introduced as a component of the rhenium-platinum antitumor system, nevertheless it did show anticancer activity close to *cis*-[Re₂(C₃H₇COO)₂Cl₄(H₂O)₂] (Fig. 6, C). This fact requires more detailed further investigations.

Thus, the use of the rhenium-platinum antitumor system eliminated the toxic influence of malignancy and cisplatin on RBC state. Such properties of the rhenium compounds should not be explained only by RBC membrane stabilizing properties as it was possible in experiments *in vitro*, and to our mind involve bone marrow processing. This statement was shown in our further experiments with bone marrow investigations [87]. Bone marrow structure and cell numbers of cisplatin-treated rats showed a deep depression of erythroid germ, decrease in the number of juvenile, mature forms of erythroid cells and polychromatophilic normoblasts, that is followed by decrease in the RBC production to the bloodstream. Introduction of the rhenium-platinum system led to up to 3-fold increase in erythroblasts, basophilic and polychromatophilic normoblasts compared to group T8+cisPt. Moreover, the appearance of single polychromatophilic normoblasts with two nucleus and single megakaryocytic cells was found under the influence of the rhenium compounds introduction.

These investigations demonstrated that dirhenium(III) compounds as a part of the Re-Pt system had anti-anemic properties, influenced positively morphological and biochemical parameters of blood and erythroid germ of the bone marrow, effectively




Fig. 6. Hemolytic erythrograms of rats RBC. **A** – Intact animals (solid), group T8 + cisPt (dash). **B** – Groups of tumor-bearing rats with introduction of rhenium–platinum system where the rhenium components were: cis-Re₂(C₃H₇COO)₂Cl₄(H₂O)₂ (solid) and cis-Re₂(C₃H₇COO)₂Cl₄(H₂O)₂ (dash). **C** – Hematocrit (red), quantity of RBC morphological forms (discocytes – blue, echinocytes – green, destroyed forms – black) in blood of rats under influence of rhenium–platinum antitumor system, where Re1 – Re₂(i-C₃H₇COO)₄Cl₂; Re2 – cis-Re₂(AdCOO)₂Cl₄(CH₃CN)₂; Re3 – cis-[Re₂(GABA)₂Cl₅(H₂O)₂]Cl; Re4 – cis-Re₂(C₃H₇COO)₂Cl₄(H₂O)₂, trans-Re₂(C₃H₇COO)₂Cl₄

increased hemoglobin levels, hematocrit, state of red blood cells and decreased content of pathological forms of RBC together with antineoplastic properties in the model of tumor growth.

As pathogenesis of the cancer anaemia involves combination of a shortened erythrocyte survival in the circulation with the failure of the bone marrow to increase red cell production, attempts have been made to find enhancement of platinum-based drugs with recombinant human erythropoietin [85]. However, erythropoietin corrected anemia but did not improve cancer control or survival of patients. Thus, we may conclude, that rhenium compounds have their own anticancer properties and, furthermore, antihemolytic ability and both can be independently executed in the model of tumor growth.

Development of tumors and T8 carcinoma followed by a free radical burst usual for malignancy

development [88-90] led to accumulation of malonic dialdehyde (MDA) in plasma of tumor-bearing rats (Fig. 7, A, B, group T8) as a result of intensive approximately 4-fold peroxide oxidation of lipids (POL) in comparison to control.

Introduction of cisplatin led to approximately half lower POL intensity due to the slowing down tumor growth [91]. Introduction of dirhenium(III) **Re1–Re4** compounds with lower anticancer activity in comparison to cisplatin, nevertheless, led to lower MDA accumulation than in blood of T8-bearing animals. In the case of the rhenium-platinum system application of some rhenium compounds (Re1, Re4) decreased the intensity of POL practically to the level of intact animals. Thus, these rhenium compounds revealed their antioxidant properties in the model of tumor growth *in vivo*. This is not true again for the dirhenium(III) compound Re5 with *trans-*




Fig. 7. Level of MDA in plasma of control (C) rats and tumor-bearing rats under influence of dirhenium(III) cluster compounds (A) and rhenium–platinum antitumor system (B), where Re1 – $Re_2(i-C_3H_7COO)_4Cl_2$; Re2 – $cis-Re_2(AdCOO)_2Cl_4(CH_3CN)_2$; Re3 – $cis-[Re_2(GABA)_2Cl_5(H_2O)_2]Cl$; Re4 – $cis-Re_2(C_3H_7COO)_2Cl_4(H_2O)_2$; Re5 – $trans-Re_2(C_3H_7COO)_2Cl_4$. (C) Activity of SOD in RBC of tumor-bearing rats under introductions of the rhenium cis-dicarboxylates with alkyl ligands: 1 – methyl; 2 – propyl; 3 – isobutyl; 4 – pivalyl; 5 – $trans-Re_2(C_3H_7COO)_2Cl_4$

orientation of carboxylic groups around cluster fragment (Fig. 7, A, B, Re5).

These abilities to decrease POL intensity depended on the structure of dirhenium(III) com-

pounds and were shown to be realized in other tissues of tumor-bearing xenografts and in other models with depleted redox state. Antioxidant properties of some dirhenium(III) compounds were higher than

those of well-known antioxidants, for example, alpha-tocopherol in the model of chemically induced anemia [35]. If the introductions of the known antioxidants led to a decrease in the intensity of POL up to 1.5-2-fold, the introduction of dirhenium(III) complexes reached the 4-5 and more times efficacy. The mechanism of action of the known antioxidants is based on the interaction of radicals with their conjugated π -bonds (for example vitamins A, E) with formation of a stable unit, which interrupts the radical chain reaction [92]. As it was shown above, the quadruple bonded cluster rhenium fragment easily binds electrons of radicals on the energetically low δ^* -antibonding orbital in three-stage reaction. Some metal-organic compounds with antioxidant properties are known [93], but their antioxidant properties are realized due to the existence of the π -unsaturated ligands, for example, of polyphenol or flavonoid nature. Quadruply bonded dirhenium compounds thus represent a new class of highly effective δ -antioxidants that are, given their nontoxicity, are very promising medicines.

The antioxidant and anticancer properties of dirhenium dicarboxylates of *cis*- and *trans*-configuration with different length of organic ligands in the model of tumor growth were studied and their different ability to activate superoxidodismutase (SOD) together with different antioxidant properties and similar antitumor effect were studied [91]. Dirhenium(III) *cis*-dicarboxylates were characterized by higher degree of activation of erythrocyte SOD in comparison to *trans*-isomer (Fig. 7, C).

The dependence between the structure of dirhenium (III) dicarboxylates and their ability to activate SOD was the reason to investigate the process of their interaction with proteins. We investigated differences in the interactions between binuclear cluster rhenium(III) compounds of *cis*- and *trans*-configuration with native bovine serum albumin (BSA) and human serum albumin (HSA) by methods of electronic absorption spectroscopy, tryptophan fluorescence and circular dichroism spectroscopy [94]. It was shown that in the process of interaction of both compounds with proteins the formation of the different complexes took place via His moieties with preservation of quadruple Re-Re bond. *Trans*-isomer interacted with molecular environment of Trp-214 (HSA) and Trp-212 (BSA) in hydrophobic pocket of the IIA subdomain of homological proteins. For the *cis*-isomer more complex mechanism took place that included not only the sub-domain IIA, but also at

least one more site of binding of the rhenium substance in the subdomain IB of the protein. Different changes in the secondary structure of the homological proteins were shown in the complexes with configuration isomers. Similar investigations were accomplished with native bovine erythrocyte SOD with the changing of the method of Trp-fluorescence on Tyr-fluorescence [95]. Binding of both complexes to His moieties and changing of the secondary structures of the enzyme did not influence its active center. Even more, for *cis*-dicarboxylate the SOD-like activity was demonstrated to be on the first minutes of the xantine-oxidase reaction, in contrast to *trans*-dicarboxylate. The studied features of the interaction between rhenium compounds and SOD *in vitro* explained only partly the strong activation of SOD in the experiments *in vivo*, shown above.

SOD-like activity, shown later for other rhenium compounds and their ability to decompose hydrogen peroxide like catalase (CAT, approximately 30-40% in comparison to native enzyme CAT, unpublished results) made certain impact on their ability to diminish oxidative stress and opened one more direction of application of the rhenium cluster compounds as SOD and CAT-mimetics. For more effective antioxidant intervention the use of metal-organic compounds with SOD- and CAT-like activity on the base of manganese [96] and cerium [97] were shown.

How antioxidants may be anticancer agents: antioxidants have been suggested to inhibit NF- κ B activation by scavenging reactive oxygen intermediates that act as signaling molecules to activate the NF- κ B pathway and by directly inhibiting IKK kinase activity by modifying critical Cys residues in the IKK kinase activation loop [98, 99]. For example, chemical modification of the curcumin molecule led to more potent inhibitors curcuminoids of NF- κ B activity than curcumin, while exhibiting both anti-inflammatory and anticancer activities [100, 101].

Influence of the rhenium cluster compounds on the state of the liver and kidneys requires special survey, as to our knowledge, there are no liver and kidneys protectors of metal-organic origin. In short: as nontoxic antioxidants, dirhenium(III) compounds influenced positively the state of the liver and kidney and prevented cisplatin-induced nephro- and hepatotoxicity [102, 103]. Although the mechanisms underlying the side-effects induced by cisplatin in the liver and kidneys tissues are not understood clearly, it was attributed to the combination of multiways, such as

generation of reactive oxygen species, which could interfere the antioxidant defense system and result in oxidative damage in different tissue and reaction with thiols in proteins and glutathione, which could cause cell dysfunctions [103]. Several antioxidants were tested in the animal model to find optimum combinations to prevent hepato-toxicity of cisplatin [104-107], and the conclusion was made about possible success which could be found in combinations of antioxidants. Dirhenium(III) compounds were found by us as unique antioxidants in decreasing intensity of POL (MDA level was found to be depleted to normal levels) in the liver and kidney tissues in experiments not only on tumor-bearing rats and use of cisplatin but also in the models of acute chemical intoxication [67-69]. Histopathology of the tissues, level of diagnostic enzymes, experiments on isolated hepatocytes and other models of kidney and liver injuries confirmed protective abilities of rhenium substances. Comparative studies of hepato- and nephro-protective properties of the compounds showed better results for dirhenium(III) carboxylates ligands derived from adamantanic acid. A tentative scheme of influence of cluster rhenium compound with quadripol bonds on erythropoiesis through regulation of synthesis of erythropoietin in kidneys was proposed [87].

Interaction of the rhenium(III) compounds with DNA and nucleobases

Interaction with DNA is still considered to be crucial in our choice among anticancer agents, nevertheless we know that any substance binds to a lot of non-nucleic acids targets being introduced to an organism. Our recent findings showed that dirhenium(III) complexes bind to nucleobases and supercoiled natural DNA [55, 108].

To probe the binding of DNA to *cis*- $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2\text{DMSO}$, the electronic absorption spectra, obtained by titrating calf timus DNA (CT-DNA) with solutions of the compound, were performed and are depicted in Fig. 8, A.

It is notable that the electronic absorption spectra traces of CT-DNA exhibit pronounced hyperchromism in the presence of increasing amounts of the rhenium compound. The DNA band at ~ 260 nm arises from the π - π^* transitions of the nucleic acid bases. Changes in the intensity and slight wavelength shifts of this characteristic band reflect the corresponding structural modifications of the DNA, which include changes in stacking, disruption

of the hydrogen bonds between complementary strands, covalent binding of the DNA bases, intercalation of aromatic rings and others. For example, hypochromism and red-shifting of the band at 260 nm are associated with intercalative binding of the complex between the DNA base pairs. The extent of hypochromism is commonly consistent with the strength of the intercalative interaction. On the other hand, hyperchromism of the absorption band at 260 nm involves non-intercalative binding and usually results from disruption of the DNA double helical structure. The hyperchromism observed for the CT DNA, induced by the addition of *cis*- $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2\text{DMSO}$, implies that its binding mode is not intercalative (intercalation is not possible for this compound), but most likely, it involves unwinding of the DNA with possible covalent interactions between the dirhenium(III) complex and the nucleic acid bases (the extent of DNA unwinding has been correlated with the formation of monofunctional or bifunctional covalent adducts by cisplatin [32]). Moreover, the new absorption band that appears at ~ 330 nm at higher complex concentrations, indicates the formation of a new DNA- *cis*- $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2\text{DMSO}$ adduct, which also supports covalent binding of the rhenium compound to CT-DNA. The covalent binding mode of the CT-DNA to the rhenium compound is also corroborated by the fact that coordination of the model nucleobase 9-ethyladenine to the dirhenium core via sites N6/N1 is known.

The calculated value of binding constant was: $K_b 2.2 \times 10^3 \text{ M}^{-1}$. As expected, the determined K_b value is lower than the values reported for the classical DNA intercalator ethidium bromide ($1.4 \times 10^6 \text{ M}^{-1}$) and for other complexes bearing intercalating groups; this K_b value indicates that the compound binds to DNA with a lower affinity than the classical intercalators but it is compared well with the magnitude of the binding constants for other non-intercalating complexes.

The interactions of transition metal complexes with DNA have been investigated by supercoiled plasmid DNA cleavage experiments, which in some cases, are associated with redox-active or photoactivated metal complexes. Supercoiled DNA cleavage entails relaxation of the supercoiled circular pUC18 DNA into the nicked circular and linear forms. When circular plasmid DNA is subjected to electrophoresis, the fastest migration is observed for the supercoiled form of DNA (Form I). If one strand is




Fig. 8. **A** – Electronic absorption spectra of CT-DNA upon addition of $\text{cis-Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2\text{DMSO}$ in different molar ratio; **B** – Electrophoregrams applying to the interaction of pUC18 plasmid with increasing concentration of $\text{cis-Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2\text{DMSO}$ (a); in the presence of hydrogen peroxide (b); in the presence of mercaptoethanol (c). Lanes P – untreated plasmid; 1 – 10 μM , 2 – 20 μM , 3 – 40 μM , 4 – 80 μM , S – standart. **C** – Reaction between $\text{Re}_2(\text{i-C}_3\text{H}_7\text{COO})_4\text{Cl}_2$ (**I**) and 9-R-GuaH, R = Me, Et

cleaved, the supercoiled form relaxes and produces a slower moving open circular form called DNA (Form II). If both strands are cleaved, a linear form of DNA (Form III) is generated, which migrates at a position between Forms I and II in the electrophoresis gel.

Agarose gel electrophoresis studies of plasmid pUC18 were performed in the presence of $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2(\text{CH}_3)_2\text{SO}$ and the gels obtained, with the DNA cleavage induced by increasing concentrations of the complex, are illustrated in Fig. 8, B. The gradual conversion of the supercoiled Form I to a mixture of supercoiled (Form I) and (Form II) DNA takes place and increasing amounts of Form II are produced with higher concentrations of $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2(\text{CH}_3)_2\text{SO}$ (Fig. 8, B, lanes 1-4, concentration of the complex 10, 20, 40 and 80 μM , respectively). These findings indicate unwinding and the strong DNA-cleaving abilities of the dirhenium complex. Moreover, binding of the plasmid DNA to the rhenium complex results in decreased mobility of Form I (lanes 1-4), which indicates changes in the DNA conformation caused by kinking of the duplex induced by the metal binding. Similar observations for cisplatin have been attributed primarily to the formation of intrastrand bifunctional 1,2-Pt(GG) and 1,2-Pt(AG) adducts inducing DNA bending at the lesion sites. Accordingly, the reduced mobility of the Form I in the presence of $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2(\text{CH}_3)_2\text{SO}$ (lanes 1-4) suggests that the rhenium complex most likely binds covalently to DNA as has been proposed for other metal complexes which exhibit similar DNA mobility decrease in the gel electrophoresis assays. The presence of the slowest moving bands in Fig. 8, B a (slower than Form II) indicates formation of high molecular weight adducts that may be explained by the formation of DNA-rhenium compound inter-strand-strand adducts similar to cisplatin and dirhodium compounds.

Interestingly, a significantly different electrophoretic behavior of the supercoiled plasmid DNA+rhenium compound is observed in the presence of H_2O_2 (Fig. 8, B, lanes 1-4): under these conditions, increasing the concentration of the complex leads to less Form II as compared to the corresponding lanes in Fig. 8, B B (lanes 1-4); additionally, it leads to a mixture of supercoiled (Form I) and linear DNA (Form III) with decreasing amounts of Form I and increasing amounts of Form III (Fig. 8, B, lanes 1-3). In lane 4 of the electrophoresis gel (Fig. 3, b)

there are no traces of any form of the plasmid, which is the result of hydrolysis taking place under high concentration of I and hydrogen peroxide. These results show the enhanced nuclease activity of the complex in the presence of H_2O_2 . In this vein, it is known that cisplatin induces production of high concentrations of hydroxyl radical and reactive oxygen species (by up to 70%) in cells and tissues.

In the presence of mercaptoethanol (Fig. 8, B, B 3c), the cleaving ability of the complex is also enhanced but no Form III and high molecular weight fragments are observed as compared to $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2(\text{CH}_3)_2\text{SO}$ only (Fig. 8, B, 3a). Taking into account that in the presence of H_2O_2 and 2-mercaptoethanol (control lanes, Pb and Pc, Fig. 8, B, 3b,c), no significant amounts of Form II III are observed, it is concluded that DNA strand scission takes place only in the presence of the rhenium complex. These findings indicate that the DNA interactions with $\text{Re}_2[(\text{CH}_3)_3\text{CCOO}]_2\text{Cl}_4 \cdot 2(\text{CH}_3)_2\text{SO}$ are redox-activated.

Experiments *in vitro* showed possibilities of the dirhenium complexes to bind to nucleobases (Fig. 8, C) [108].

The DNA binding studies support relatively strong interactions of rhenium compounds with DNA by alteration of the DNA conformation, groove binding, likely formation of covalent interstrand adducts, disruption, kinking and unwinding of the DNA duplex as well as supercoiled DNA cleavage. These effects render natural DNA a plausible target of the dirhenium(III) compounds in living cells and provide insight about their anticancer activity.

As cisplatin is a pro-oxidant, the redox-activating properties of the rhenium compounds may explain the efficacy of the Re-Pt antitumor system.

As a whole, quadruple bond is a unique bond absent among biologically occurring molecules, its chemistry and biochemistry is arising to bring a lot of discoveries being developed. Elaboration of the synthetic methods described herein presents possibility to create a dirhenium(III) quadruple-bonded compound of any class with organic, haloid or phosphate ligands or their mixture to our choice. Quadruple Re-Re bond supports the lower valence state of the metal that may be important in 'prodrug strategy', i.e. entrapping by cancer cells the metal atom may change its valence state to be a good catalyst of the cellular redox processes crucial for survival. Shown ability to coordinate different ligands in diverse manner around Re_2^{6+} -coordination centre pre-

sents a possibility to involve diverse (also specific) ligands to coordination sphere thus to move from 'dirty' drug to more specific targeting. For example, involvement of amino acids in this process, gives a perspective to work with short peptides. By design of dirhenium(III) compounds with ligands of high specific ability to bind to well-defined target in cancer cells we could operate more tolerant to other cells and to exploit both the redox regulation potential of the cluster fragment and its coordination ability as well.

Dependence of the absorption bands position in EAS area of $\delta \rightarrow \delta^*$ transition from the quantity of bidentate ligands around cluster fragments in dirhenium(III) compounds gave an expectancy to watch interactions with lipids even inside a liposome. The process of substitution around cluster rhenium fragment shown in such a way inside a nano – vehicle may make definite impact on the activity of the quadruple bond as presented more functional potential for reaction ability. Encapsulation of cluster rhenium compounds to lipid coating has not only protective but activation significance for the quadruple Re–Re bond. These findings have their own significance for nanobiotechnology. Different approaches are used by us now to elaborate solid lipid nanoparticles, nanoliposomes with mixed composition inside that opens perspective to take control of drug release and to use nanobased combinational therapy.

Antiradical and antioxidant properties of the dirhenium(III) compounds are of great interest as represent a new type of antioxidant activity. Really, antiradical and antioxidant activity of the known natural and synthetic substances is based on their ability to accept and delocalize an electron through the system of conjugated π -bonds. Here we have shown the ability of quadruple bond with δ -component to scavenge an unpaired electron and to diminish oxidative stress, thus we have a range of pharmacophores – antioxidant units in our hands with different antioxidant capacities which may be chosen according to requirements.

Dirhenium(III) compounds have their own anticancer activity that is mainly conditioned by dirhenium cluster fragment but depends on the nature of the ligands; the synergistic effect in application of cisplatin and dirhenium(III) cluster compounds showed eliminated tumor growth and cancer cells with high efficiency; combination of two metal based compounds switched some additional signal trans-

duction pathways crucial for cancer cells survival or death. Only some aspects of the mechanism of anticancer activity of the rhenium-platinum system have been studied.

Identifying multiple molecular targets for effective combinations of preventive agents is a major focus of contemporary chemoprevention or chemotherapeutic study. As cisplatin is a multifunctional molecule, it can bind to a lot of targets in the living cell. Dirhenium(III) compounds are more multifunctional than cisplatin due to their more complicated structure and more multitargeting should be expected. They interact with DNA, may enhance cisplatin accumulation, interfere with the glutathione system, change intracellular ATP-level or manipulate other biochemical pathway(s) of the cancer cells that altogether led to mighty synergistic effect of both compounds.

Dirhenium(III) compounds as antioxidants behaved as antihemolytics, hepato- and nephroprotectors. The idea of regulation of redox potential in cancer cells is central to our mind. Cancer cells can generate large amounts of hydrogen peroxide, which may contribute to their ability to mutate and damage normal tissues, and, moreover, facilitate tumor growth and invasion. It has been suggested that persistent oxidative stress in tumor cells could partly explain some important characteristics of cancer, such as activated proto-oncogenes, genomic instability, drug resistance, etc. Thus, application of antioxidants such as dirhenium(III) compounds can result not only in lowering of oxidative stress by distinguishing the extent of radical process, but also may have regulatory functions.

Overall, the above results strongly indicate that application of nontoxic dirhenium(III) compounds with quadruple bond is an emerging concept in the development of new anticancer therapeutics.

Future perspectives

Rhenium-platinum antitumor system may be effective in a lot of human cancer types and could be a mighty weapon in our war against cancer. Dirhenium(III) compounds with unique quadruple bond represent a perspective platform for development of new anticancer therapeutics as a useful component in cancer combined therapies or as pharmacophore units with antioxidant properties in design of future medicines. Quadruple-bonded rhenium(III) compounds may be used not only in treatment of cancer but also in any diseases with depleted redox

states as antihemolytics, hepato- and nephroprotectors.

Acknowledgements

The authors gratefully acknowledge Prof. K. R. Dunbar and Dr. Philippe Collery for their participation, kind attention and stimulating discussions of our work; colleagues from Oles Gonchar Dnipropetrovsk National University and Ukrainian State University of Chemical Technology for their help.

Financial and competing interests

The work was supported by Ministry of Education and Science, Youth and Sport of Ukraine (grants 0107U000528 and 0111U000111), Fulbright and DAAD grants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflicts with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

ПРОТИПУХЛИННІ СИСТЕМИ РЕНІЙ–ПЛАТИНА

О. В. Штеменко¹, Н. І. Штеменко²

¹Український державний хіміко-технологічний університет, Дніпро;
²Інститут біохімії ім. О. В. Палладіна
НАН України, Київ;
e-mail: n.shtemenko@i.ua

Огляд присвячено розгляду процесів виявлення протипухлинних й інших біологічних властивостей кластерних сполук диренію(III) з почверним зв'язком та їх синергізму із цисплатином. Зокрема, описано роботу протипухлинної системи реній–платина, яка створюється за одночасного введення ренієвих і платинових сполук. Серед відомих металомісних потенційних антиракових ліків диреній(III)-сполуки вирізняються значною антирадикальною і антиоксидантною активністю, обумовленою ненасиченістю почверного зв'язку. Такі переваги металомісних сполук як широкі редокс-хімічні властивості слід використовувати для створення ефективних протиракових сполук. Сумісне введення декількох препаратів приводить до синергічного ефекту або/також до зниження токсичності платинидів і є перспективним у протираковій терапії. Представлена робота висвітлює такі питання: синтез диреній(III)-сполук із по-

чверним зв'язком (коротко) та їхні спектральні і антирадикальні властивості; взаємодія диренієвих(III) сполук із ліпідами та формування наноліпосом; взаємодія диреній(III)-сполук з еритроцитами та їхня антигемолітична активність у моделях гемолітичної анемії; антиракова активність диренієвих кластерів та робота системи реній–платина; антианемічна і антиоксидантні властивості кластерних сполук ренію в моделі пухлинного росту; взаємодія диреній(III)-сполук із нуклеїновими основами і ДНК. Розглянуто також деякі сучасні тенденції в розвитку біоорганічної і медичної хімії стосовно ефективності системи реній–платина: використання комбінаційної терапії та наноматеріалів; залучення біологічно активних лігандів, стратегія редоксактивації і т.і.

Ключові слова: реній, платина, протипухлинна активність, антигемолітики, гепато- та нефростабілізуюча активність.

ПРОТИВООПУХОЛЕВЫЕ СИСТЕМЫ РЕНИЙ–ПЛАТИНА

А. В. Штеменко¹, Н. И. Штеменко²

¹Украинский государственный химико-технологический университет, Днепр;
²Институт биохимии им. А. В. Палладина
НАН Украины, Киев;
e-mail: n.shtemenko@i.ua

Обзор посвящен рассмотрению процессов проявления противоопухолевых и других биологических свойств кластерных соединений дирения(III) с четверной связью и их синергизму с цисплатином. В частности, описана работа противоопухолевой системы реній–платина, которая создается при одновременном введении рениевых и платиновых соединений. Среди известных металлосодержащих потенциальных противораковых препаратов дирений(III)-соединения отличаются значительной антирадикальной и антиоксидантной активностью, обусловленной ненасыщенностью четвертичной связи. Такие преимущества металлоорганических соединений как более выраженные редокс-химические свойства следует использовать для создания эффективных противораковых препаратов. Совместное введение нескольких препаратов приводит к синергическому эффекту или/также к снижению токсичности платини-

дов и является перспективным в противораковой терапии. Представленная работа освещает следующие вопросы: синтез дирений(III)-соединений с четвертичной связью (кратко) и их спектральные и антирадикальные свойства; взаимодействие дирений(III)-соединений с липидами и формирование нанолипосом; взаимодействие дирений(III)-соединений с эритроцитами и их антигемолитическая активность в моделях гемолитической анемии; антираковая активность дирениевых кластеров и работа системы рений–платина; антианемическая и антиоксидантные свойства кластерных соединений рения в модели опухолевого роста; взаимодействие дирений(III)-соединений с нуклеиновыми основаниями и ДНК. Рассмотрены также некоторые современные тенденции в развитии биоорганической химии и медицинской химии в связи с эффективностью системы рений–платина: использование комбинационной терапии и наноматериалов; вовлечение биологически активных лигандов, стратегия редоксактивации и т.д.

Ключовые слова: рений, платина, противоопухолевая активность, антигемолитики, гепато- и нефростабилизирующая активность.

References

- Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Germany: Wiley-VCH: Weinheim, 1999; 576 p.
- Graf N, Lippard SJ. Redox activation of metal-based prodrugs as a strategy for drug delivery. *Adv Drug Deliv Rev.* 2012; 64(11): 993-1004.
- Hambley TW. Chemistry. Metal-based therapeutics. *Science.* 2007; 318(5855): 1392-1393.
- Bruijninx PC, Sadler PJ. New trends for metal complexes with anticancer activity. *Curr Opin Chem Biol.* 2008; 12(2): 197-206.
- Hambley TW. Developing new metal-based therapeutics: challenges and opportunities. *Dalton Trans.* 2007; (43): 4929-4937.
- Reisner E, Arion VB, Keppler BK, Pombeiro AJL. Electron-transfer activated metal-based anticancer drugs. *Inorg Chim Acta.* 2008; 361(6): 1569-1583.
- Hillard EA, Jaouen G. Bioorganometallics: future trends in drug discovery, analytical chemistry, and catalysis. *Organometallics.* 2011; 30(1): 20-27.
- Clarke MJ, Zhu F, Frasca DR. Non-platinum chemotherapeutic metallopharmaceuticals. *Chem Rev.* 1999; 99(9): 2511-2534.
- Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK. Antitumour metal compounds: more than theme and variations. *Dalton Trans.* 2008; (2): 183-194.
- Sun RW, Ma DL, Wong EL, Che CM. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. *Dalton Trans.* 2007; (43): 4884-4892.
- Sorasaene K, Fu PK, Angeles-Boza AM, Dunbar KR, Turro C. Inhibition of transcription *in vitro* by anticancer active dirhodium(II) complexes. *Inorg Chem.* 2003; 42(4): 1267-1271.
- Chifotides HT, Fu PK, Dunbar KR, Turro C. Effect of equatorial ligands of dirhodium(II,II) complexes on the efficiency and mechanism of transcription inhibition *in vitro*. *Inorg Chem.* 2004; 43(3): 1175-1183.
- Chifotides HT, Dunbar KR. Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA. *Acc Chem Res.* 2005; 38(2): 146-156.
- Guo Z, Sadler PJ. Metals in medicine. *Angew Chem Int Ed.* 1999; 38(11): 1512-1531.
- Oliynik SA, Shtemenko NI, Gorchakova NO, Shtemenko AV, Zatozki IV, Pirozhkova-Patalah IV, Patalah DD, Pedan LI. Toxicology of rhenium compounds: a glance on the problem. *Modern Probl Toxicol.* 2001; (1): 3-12. (In Ukrainian).
- Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. *Chem Rev.* 2007; 107(5): 1387-1407.
- van Zutphen S, Reedijk J. Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. *Coord Chem Rev.* 2005; 249(24): 2845-2853.
- Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. *Nat Rev Drug Discov.* 2005; 4(4): 307-320.
- Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. *Curr Med Chem.* 2003; 10(3): 257-266.

20. Denny WA. Prodrug strategies in cancer therapy. *Eur J Med Chem.* 2001;36(7-8): 577-595.
21. Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. *Chem Rev.* 2003; 103(3): 645-662.
22. Lee MS. Systematic prioritization of cancer combination therapies: are we really on target? *Future Med Chem.* 2012; 4(4): 387-389.
23. Facy O, Radais F, Ladoire S, Delroeu X, Tixier H, Ghiringhelli F, Rat P, Chauffert B, Ortega-Deballon P. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis. *J Exp Clin Cancer Res.* 2011; 30: 4.
24. Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y, Zheng D. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. *BMC Cancer.* 2011; 11: 54.
25. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity *in vivo*. *Neoplasia.* 2011; 13(5): 483-491.
26. Kotelnikova A. S., Tronev V. G. Investigation complex compounds of bivalence rhenium. *Zh Neorg Khim.* 1958; 3(4): 1008-1027. (In Russian).
27. Cotton FA, Harris CB. Molecular orbital calculations for complexes of heavier transition elements. III. The metal-metal bonding and electron structure of $\text{Re}_2\text{Cl}_8^{2-}$. *Inorg Chem.* 1967; 6(5): 924-929.
28. Koz'min PA. Quadruple metal-metal bond: history and outlook. *Chem Intelligencer.* 1996; 4: 32-36.
29. Cotton FA, Murillo CA, Walton RA. Multiple bonds between metal atoms (3rd Edition). Springer Science and Business Media, New York, NY, USA, 2005; 818 p.
30. Haycock DE, Urch DS, Garner CD, Hillier IH, Mitcheson GR. Direct evidence for the quadruple metal-metal bond in the octachlorodimolybdenum(II) ion, $[\text{Mo}_2\text{Cl}_8]^{4-}$, using X-ray emission spectroscopy. *J Chem Soc Chem Commun.* 1978; (6): 262-263.
31. Shtemenko AV, Kozhura OV, Pasenko AA, Domasevitch KV. New octachlorodirhenate(III) salts: solid state manifestation for a certain conformational flexibility of the $[\text{Re}_2\text{Cl}_8]^{2-}$ ion. *Polyhedron.* 2003; 22(12): 1547-1552.
32. Golovaneva IF., Bovykin BA, Shtemenko AV, Kotelnikova AS, Misailova TV, Shram VP. Spectrophotometric study of the process of formation binuclear rhenium(III) halogenocarboxylates under reducing KReO_4 in the mixture of acids. *Zhurn Neorg Khim.* 1987; 32(2): 387-393. (In Russian).
33. Shtemenko AV, Golichenko AA, Domasevitch KV. Synthesis of novel tetracarboxylato dirhenium(III) compounds and crystal structure of $[\text{Re}_2(\text{1 Adamantylcarboxylate})_4\text{Cl}_2] \cdot 4\text{CHCl}_3$. *Z Naturforsch B.* 2001; 56(4/5): 381-385.
34. Golichenko AA, Shtemenko AV. Cluster rhenium(III) complexes with adamantanecarboxylic acids: Synthesis and properties. *Russ J Coord Chem.* 2006; 32(4): 242-249.
35. Shtemenko NI, Zabitskaya ED, Berzenina OV, Yegorova DE, Shtemenko AV. Liposomal forms of rhenium cluster compounds: enhancement of biological activity. *Chem Biodivers.* 2008; 5(8): 1660-1667.
36. Kovtun GA, Kameneva TM, Golichenko AA, Shtemenko AV. Catalysis of benzyl alcohol oxidation chains breaking with rhenium dinuclear cluster $[\text{Re}_2(\text{O}_2\text{CCH}_2)_2\text{Cl}_4 \cdot 2\text{H}_2\text{O}]$. *Dopov Nac Akad Nauk Ukr.* 2005; (5): 141-144. (In Russian).
37. Shtemenko AV, Tretyak SY, Golichenko AA. Interaction of quadruple bonding rhenium unit with free radicals. *Chem J Mold.* 2007; 2(1): 93-97.
38. Shtemenko A, Golichenko A, Tretyak S, Shtemenko N, Randarevich. M. Synthesis and antiradical properties of dirhenium cluster compounds. Metal ions in biology and medicine. *John Libbey Eurotext Ltd.* 2008; 10: 229-234.
39. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. *Cancer Chemother Pharmacol.* 2011; 68(4): 945-950.
40. Ramachandran S, Quist AP, Kumar S, Lal R. Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. *Langmuir.* 2006; 22(19): 8156-8162.
41. Carvalho Júnior AD, Vieira FP, Melo VJ, Lopes MT, Silveira JN, Ramaldes GA, Garnier-

- Suillerot A, Pereira-Maia EC, Oliveira MC. Preparation and cytotoxicity of cisplatin-containing liposomes. *Braz J Med Biol Res.* 2007; 40(8): 1149-1157.
42. Kulik GJ, Pivnyuk VM, Nosko MM, Todor IN, Chekhun VF. Liposomal drugs approach to overcome drug resistance to cisplatin. *Onkologiya.* 2009; 11(1): 76-80.
43. de Kroon AI, Staffhorst RW, Kruijff Bd, Burger KN. Cisplatin nanocapsules. *Methods Enzymol.* 2005; 391: 118-125.
44. Li Z, Shtemenko NI, Yegorova DY, Babiy SO, Brown AJ, Yang T, Shtemenko AV, Dunbar KR. Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity. *J Liposome Res.* 2015; 25(1): 78-87.
45. Shtemenko OV, Zeleniuk MA, Shtemenko NI, Verbyts'ka IaS. Spectrophotometric study of the interaction between rhenium complexes and phosphatidylcholine during liposome formation. *Ukr Biokhim Zhurn.* 2002; 74(6): 91-96. (In Ukrainian).
46. Sowemimo-Coker SO. Red blood cell hemolysis during processing. *Transfus Med Rev.* 2002; 16(1): 46-60.
47. Shtemenko N., Oliinik S., Shtemenko O., Pirozhkova-Patalakh I. Antihemolytic activity of cluster complexes of rhenium with organic ligands. *Dopov Nac Akad Nauk Ukr.* 2001; (6): 194-198. (In Ukrainian).
48. Shraer TI, Krejnes VM, Golubchikova NA, Ustjantzeva IM, Meljantzeva LP, Lagunova NT. Biological action of liposomes on main pathogenetic mechanisms of inflammation. *J Liposome Res.* 1994; 4(1): 281-288.
49. Shtemenko N, Collery P, Shtemenko A. Dichlorotetra-mu-Isobutyratodirhenium(III): enhancement of cisplatin action and RBC-stabilizing properties. *Anticancer Res.* 2007; 27(4B): 2487-2492.
50. Eastland GW Jr, Yang G, Thompson T. Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice. *Methods Find Exp Clin Pharmacol.* 1983; 5(7):435-438.
51. Chekhun VF, Lebed OI, Tryndyak VP, Makovetsky VP, Todor IN, Kulik GI. Structural alterations of plasma membranes of Guerin's carcinoma cells upon the development of resistance to doxorubicine. *Exp Oncol.* 2002; 24: 279-283.
52. Yurchenko OV, Todor IN, Tryndyak VP, Kovtonyuk OV, Solyanik GI, Kulik GI, Chekhun VF. Resistance of Guerin's carcinoma cells to cisplatin: biochemical and morphological aspects. *Exp Oncol.* 2003; 25: 64-68.
53. Shtemenko NI, Collery P, Shtemenko AV. The novel rhenium and platinum antitumor systems. *J Biol Inorg Chem.* 2007; 12(Suppl 1): S22.
54. Shtemenko AV, Collery P, Shtemenko NI, Domasevitch KV, Zabitskaya ED, Golichenko AA. Synthesis, characterization, *in vivo* antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin. *Dalton Trans.* 2009; (26): 5132-5136.
55. Shtemenko NI, Chifotides HT, Domasevitch KV, Golichenko AA, Babiy SA, Li Z, Paramonova KV, Shtemenko AV, Dunbar KR. Synthesis, X-ray structure, interactions with DNA, remarkable *in vivo* tumor growth suppression and nephroprotective activity of cis-tetrachloro-dipivalato dirhenium(III). *J Inorg Biochem.* 2013; 129: 127-134.
56. Leus IV, Shamelashvili KL, Skoryk OD, Tretiak SIu, Golichenko OA, Shtemenko OV, Shtemenko NI. Antioxidant and antitumor activity of dirhenium dicarboxylates in animals with Guerin carcinoma. *Ukr Biokhim Zhurn.* 2012; 84(3): 72-81. (In Ukrainian).
57. Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Steele VE, Wattenberg LW. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice. *Carcinogenesis.* 2004; 25(2): 197-201.
58. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. *Chem Rev.* 2007; 107(5): 1387-407.
59. Angeles-Boza AM, Chifotides HT, Aguirre JD, Chouai A, Fu PK, Dunbar KR, Turro C. Dirhodium(II,II) complexes: molecular characteristics that affect *in vitro* activity. *J Med Chem.* 2006; 49(23): 6841-6847.
60. Aguirre JD, Angeles-Boza AM, Chouai A, Pellois JP, Turro C, Dunbar KR. Live cell cytotoxicity studies: documentation of the interactions of antitumor active dirhodium compounds with nuclear DNA. *J Am Chem Soc.* 2009; 131(32): 11353-11360.

61. Chifotides HT, Lutterman DA, Dunbar KR, Turro C. Insight into the photoinduced ligand exchange reaction pathway of *cis*-[Rh₂(μ-O₂CCH₃)₂(CH₃CN)₆]²⁺ with a DNA model chelate. *Inorg Chem.* 2011; 50(23): 12099-12107.
62. Lee MS. Systematic prioritization of cancer combination therapies: are we really on target? *Future Med Chem.* 2012; 4(4): 387-389.
63. Barder TJ, Walton RA, Cotton FA, Powell GL. Tetrabutylammonium octachlorodirhenate(III). *Inorg Synth.* 1985; 23: 116-118.
64. Lippman SM, Hong WK. Cancer prevention by delay. *Clin Cancer Res.* 2002; 8(2): 305-313.
65. Kreuser ED, Keppler BK, Berdel WE, Piest A, Thiel E. Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. *Semin Oncol.* 1992; 19(2 Suppl 3): 73-81.
66. Grivicich I, Mans DR, Peters GJ, Schwartsmann G. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. *Braz J Med Biol Res.* 2001; 34(9): 1087-1103.
67. Lin WL, Li DG, Chen Q, Lu HM. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. *World J Gastroenterol.* 2004; 10(19): 2911-2915.
68. Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. *Chem Rev.* 2003; 103(3): 645-662.
69. Yu F, Megyesi J, Price PM. Cytoplasmic initiation of cisplatin cytotoxicity. *Am J Physiol Renal Physiol.* 2008; 295(1): F44-F52.
70. Bovykin AM, Omel'chenko AM, Chasova EA, Shtemenko AV. The effects of o-phenantroline-containing rhenium complexes on the properties of the bilayer lipid membranes. *Membr Cell Biol.* 1995; 8: 471-476.
71. Bovykin AM, Omel'chenko AM, Shtemenko AV, Chasova E.. The unusual ability of a rhenium(V) complex containing nicotinamide to raise the conductivity of lipid membranes. *Biophysic.* 1995; 40(3): 525-529.
72. Tomas ML, Coyle KV, Sultan M, Vaghar-Kashani A, Marcato P. Chemoresistance in cancer stem cells and strategies to overcome resistance. *Chemotherapy.* 2014; 3(1): 2-10.
73. Wu A, Zheng L, Xiao Q. How cancer outsmarts treatments: assessing drug resistance in tumors. *J Cancer Biol Res.* 2013; 1(3): 1-4.
74. Alama A, Orengo AM, Ferrini S, Gangemi R. Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? *Drug Discov Today.* 2012; 17(9-10): 435-442.
75. Chechun BF, Shishova UV. Contemporary glance on the mechanisms of tumor drug resistance. *Oncology.* 2000; 2(1-2): 11-15. (In Russian).
76. Kuluk GI, Pivnuk VM, Nosko MM. Liposomal preparations: a way to overcome drug resistance to cisplatin. *Oncology.* 2009; 11(1): 76-80. (In Russian).
77. Pande V, Ramos MJ. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. *Curr Med Chem.* 2005; 12(3): 357-374.
78. Wheatley D. Regrowth of tumour cells from supposedly terminal giant cells. *Oncology News.* 2006; 1(3): 3.
79. Moliterno AR, Spivak JL. Anemia of cancer. *Hematol Oncol Clin North Am.* 1996; 10(2): 345-363.
80. Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O'Brien M, Van Belle S, Vaupel P. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. *Oncology.* 2005; 68(Suppl 1): 12-21.
81. Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. *Cancer Chemother Pharmacol.* 2006; 57(1): 91-96.
82. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. *Int J Radiat Oncol Biol Phys.* 2005; 63(1): 25-36.
83. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Gamian A. Even a mild anemia is related to tumor aggressiveness mediated by angiogenic factors. *Exp Oncol.* 2009; 31(1): 52-56.
84. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in

- patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. *J Clin Oncol*. 1997; 15(3): 1218-1234.
85. Taylor SK. Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy? *Med Hypotheses*. 2003; 60(1): 89-93.
86. Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet*. 2003; 362(9392): 1255-1260.
87. Voronkova YS, Babiy SO, Ivans'ka LV, Shtemenko OV, Shtemenko NI. Antioxidant properties of cluster rhenium compounds and their effect on erythropoiesis of rats with Guerin carcinoma. *Ukr Biochem J*. 2015; 87(1): 99-108. (In Ukrainian).
88. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. *Antioxid Redox Signal*. 2009; 11(12): 3013-3069.
89. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. *Mol Aspects Med*. 2011; 32(4-6): 234-246.
90. Sainz RM, Lombo F, Mayo JC. Radical decisions in cancer: redox control of cell growth and death. *Cancers (Basel)*. 2012; 4(2): 442-474.
91. Leus IV, Shamelashvili KL, Skoryk OD, Tretiak Slu, Golichenko OA, Shtemenko OV, Shtemenko NI. Antioxidant and antitumor activity of dirhenium dicarboxylates in animals with guerin carcinoma. *Ukr Biokhim Zhurn*. 2012; 84(3): 72-81. (In Ukrainian).
92. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. *J Control Release*. 2006; 113(3): 189-207.
93. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. *Antioxid Redox Signal*. 2011; 15(4): 1085-1127.
94. Leus IV, Klenina IV, Zablotska KA, Golichenko OA, Shtemenko OV, Shtemenko NI. Interaction of serum albumins with cluster rhenium compounds of cis- and trans-configuration. *Biopolym Cell*. 2011; 27(6): 465-471. (In Ukrainian).
95. Shamelashvili KL, Shtemenko NI, Leus IV, Babiy SO, Shtemenko OV. Changes in oxidative stress intensity in blood of tumor-bearing rats following different modes of administration of rhenium-platinum system. *Ukr Biochem J*. 2016; 88(4): 29-39.
96. Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. *J Control Release*. 2014; 177: 34-41.
97. Pirmohamed T, Dowding JM, Singh S, Wasserman B, Heckert E, Karakoti AS, King JE, Seal S, Self WT. Nanoceria exhibit redox state-dependent catalase mimetic activity. *Chem Commun (Camb)*. 2010; 46(16): 2736-2738.
98. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF- κ B activation by small molecules as a therapeutic strategy. *Biochim Biophys Acta*. 2010; 1799(10-12): 775-787.
99. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. *Oncogene*. 2006; 25(51): 6887-6899.
100. Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TW. Inhibition of the NF- κ B signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. *Int Immunopharmacol*. 2012; 12(2): 368-377.
101. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. *Mol Cancer*. 2011; 10: 12.
102. Ivchuk VV, Polishko TM, Golichenko OA, Shtemenko OV, Shtemenko NI. Influence of antitumor system rhenium-platinum on biochemical state of the liver. *Ukr Biokhim Zhurn*. 2011; 83(3): 76-84. (In Ukrainian).
103. Babiy SA, Loskutova TF, Shtemenko NI. Changes of the state of rat kidneys under Guerin carcinoma development and use of cytostatics. *Ukr Biokhim Zhurn*. 2012; 84(3): 63-71. (In Ukrainian).
104. Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. *Toxicol Sci*. 2006; 89(2): 515-523.

105. Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. *Pharmacol Res.* 2008; 57(2): 125-131.
106. Avcı A, Cetin R, Erguder IB, Devrim E, Kilicoglu B, Candir O, Ozturk HS, Durak I. Cisplatin causes oxidation in rat liver tissues: possible protective effects of antioxidant food supplementation. *Turk J Med Sci.* 2008; 38(2): 117-120.
107. Abdel Wahab SI, Abdul AB, Alzubairi AS, Mohamed Elhassan M, Mohan S. In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa). *J Biomed Biotechnol.* 2009; 2009: 769568.
108. Shtemenko NI, Chifotides HT, Domasevitch KV, Golichenko AA, Babiy SA, Zhanyong Li, Paramonova KV, Shtemenko AV, Dunbar KR. Synthesis, X-ray structure, interactions with DNA, remarkable in vivo tumor growth suppression and nephroprotective activity of cis-tetrachloro-dipivalato dirhenium(III). *J Inorg Biochem.* 2013; 129: 127-134.

Received 23.11.2016